For the quarter ending 2026-03-31, AMPH had $762K increase in cash & cash equivalents over the period. $38,333K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net revenues | 171,171 | 719,887 | - | - |
| Payroll expense | 50,618 | 191,787 | - | - |
| Materials and supplies | 12,741 | 43,314 | - | - |
| Clinical trials expense | 1,552 | 3,038 | - | - |
| Depreciation and amortization expense | 14,348 | 56,695 | - | - |
| Stock-based compensation expense | 9,274 | 27,277 | - | - |
| Consulting and outside services expense | 10,362 | 39,771 | - | - |
| Advertising and promotional expense | 3,060 | 13,138 | - | - |
| Other segment items | 55,011 | 204,441 | - | - |
| Interest income | 2,400 | 8,679 | - | - |
| Interest expense | 6,553 | 25,481 | - | - |
| Net revenues | - | - | 191,840 | - |
| Payroll expense | - | - | 45,871 | - |
| Materials and supplies | - | - | 7,648 | - |
| Clinical trials expense | - | - | 352 | - |
| Depreciation and amortization expense | - | - | 14,129 | - |
| Stock-based compensation expense | - | - | 6,297 | - |
| Consulting and outside services expense | - | - | 9,922 | - |
| Advertising & promotional expense | - | - | 3,374 | - |
| Other segment items | - | - | 78,696 | - |
| Interest income | - | - | 10,266 | - |
| Interest expense | - | - | 6,284 | - |
| Income tax provision | 3,632 | 7,485 | 18,045 | - |
| Net income | 6,420 | 24,429 | 17,350 | 56,315 |
| Loss on disposal of assets | -4 | -6 | -1 | -32 |
| Loss (gain) on interest rate swaps and foreign currency transactions, net | - | -471 | -285 | -1,736 |
| (gain) loss on interest rate swaps and foreign currency transactions, net | 416 | - | - | - |
| Depreciation of property, plant, and equipment | 8,078 | 8,071 | 7,860 | 15,716 |
| Amortization of intangible assets | 6,270 | 6,270 | 6,269 | 12,509 |
| Operating lease right-of-use asset amortization | 2,144 | 1,646 | 1,639 | 3,221 |
| Amortization of discounts, premiums, and debt issuance costs | 761 | 866 | 885 | 1,604 |
| Share-based compensation expense | 9,274 | 6,205 | 6,297 | 14,775 |
| Changes in reserve for uncertain tax positions | - | -1,032 | - | - |
| Changes in deferred taxes, net | - | -28,660 | - | - |
| Accounts receivable, net | 4,547 | -3,232 | 13,791 | -4,192 |
| Inventories | -6,248 | -9,009 | -5,860 | 35,932 |
| Prepaid expenses and other assets | 2,326 | -9,828 | 7,941 | 5,417 |
| Income tax refunds, deposits, and payable, net | -7,742 | 20,498 | -4,122 | 8,467 |
| Operating lease liabilities | -1,415 | -1,656 | -1,591 | -2,362 |
| Accounts payable and accrued liabilities | 9,603 | -42,644 | 25,338 | 12,747 |
| Net cash provided by operating activities | 47,840 | 32,863 | 52,583 | 70,669 |
| Purchases and construction of property, plant, and equipment | 9,507 | 8,272 | 5,348 | 21,262 |
| Purchase of intangible assets | - | 0 | 0 | 2,250 |
| Purchase of investments | 22,795 | 68,305 | 35,206 | 15,619 |
| Maturity of investments | 15,502 | 16,442 | 22,527 | 51,322 |
| Debt issuance costs | - | 8 | 4 | 675 |
| Deposits and other assets | -67 | 434 | 1,592 | 2,335 |
| Proceeds from borrowing under lines of credit | - | 273 | 172 | 5,771 |
| Net cash (used in) provided by investing activities | -16,733 | -60,569 | -19,619 | 9,856 |
| Proceeds from equity plans, net of withholding tax payments | 686 | 1,982 | 379 | 494 |
| Purchase of treasury stock | 29,492 | 20,516 | 4,850 | 50,220 |
| Principal payments on long-term debt | 29 | 104 | 44 | 75 |
| Net cash used in financing activities | -30,207 | -18,373 | -4,347 | -44,705 |
| Effect of exchange rate changes on cash | -138 | -9 | -41 | 260 |
| Net increase in cash, cash equivalents, and restricted cash | 762 | -46,088 | 28,576 | 36,080 |
| Cash, cash equivalents, and restricted cash at beginning of period | 170,412 | 216,500 | 151,844 | - |
| Cash, cash equivalents, and restricted cash at end of period | 171,174 | 170,412 | 216,500 | - |
Amphastar Pharmaceuticals, Inc. (AMPH)
Amphastar Pharmaceuticals, Inc. (AMPH)